BACKGROUND: Historically, completion axillary lymph node dissection (cALND) is recommended in sentinel lymph node (SLN)-positive patients. However, the high rate of negative non-sentinel nodes (NSNs) in cALND and the reported low axillary recurrence rates have led to a more conservative approach. A risk score was developed to identify a patient's individual risk for NSN metastases. METHODS: Data of 182 SLN-positive patients who underwent cALND were used for risk score development. The risk score, consisting of pathological tumor size (≤ 20/>20 mm), lymphovascular invasion (no/yes), extracapsular extension (no/yes), size of metastases (≤ 2/>2 mm), and number of positive SLNs (1/>1), was subsequently validated on an external population (n = 180). RESULTS: The area under the receiver operating characteristic curve was 0.78 (95 % CI 0.71-0.85) in the original population and 0.78 (95 % CI 0.70-0.85) in the validation population. Based on the predicted risk for positive NSNs, three groups were defined: low risk (≤ 20 %), intermediate risk (21-50 %), and high risk (>50 %). In total, 88 patients met the Z0011 inclusion criteria and none of them had a high predicted risk. Of the 199 non-Z0011 patients, 67 (33.7 %) had low risk, 96 (48.2 %) had intermediate risk, and 36 (18.1 %) had high risk. CONCLUSION: A simple risk score, integrating just five clinicopathological variables, was developed that may assist in individual decision making regarding ALND in SLN-positive patients outside of the Z0011 trial.
BACKGROUND: Historically, completion axillary lymph node dissection (cALND) is recommended in sentinel lymph node (SLN)-positive patients. However, the high rate of negative non-sentinel nodes (NSNs) in cALND and the reported low axillary recurrence rates have led to a more conservative approach. A risk score was developed to identify a patient's individual risk for NSN metastases. METHODS: Data of 182 SLN-positive patients who underwent cALND were used for risk score development. The risk score, consisting of pathological tumor size (≤ 20/>20 mm), lymphovascular invasion (no/yes), extracapsular extension (no/yes), size of metastases (≤ 2/>2 mm), and number of positive SLNs (1/>1), was subsequently validated on an external population (n = 180). RESULTS: The area under the receiver operating characteristic curve was 0.78 (95 % CI 0.71-0.85) in the original population and 0.78 (95 % CI 0.70-0.85) in the validation population. Based on the predicted risk for positive NSNs, three groups were defined: low risk (≤ 20 %), intermediate risk (21-50 %), and high risk (>50 %). In total, 88 patients met the Z0011 inclusion criteria and none of them had a high predicted risk. Of the 199 non-Z0011 patients, 67 (33.7 %) had low risk, 96 (48.2 %) had intermediate risk, and 36 (18.1 %) had high risk. CONCLUSION: A simple risk score, integrating just five clinicopathological variables, was developed that may assist in individual decision making regarding ALND in SLN-positive patients outside of the Z0011 trial.
Authors: Andraz Perhavec; Maja Pohar Perme; Marko Hocevar; Nikola Besić; Janez Zgajnar Journal: Breast Cancer Res Treat Date: 2010-01 Impact factor: 4.872
Authors: Rosa F Hwang; Savitri Krishnamurthy; Kelly K Hunt; Nadeem Mirza; Frederick C Ames; Barry Feig; Henry M Kuerer; S Eva Singletary; Gildy Babiera; Funda Meric; Jeri S Akins; Jessica Neely; Merrick I Ross Journal: Ann Surg Oncol Date: 2003-04 Impact factor: 5.344
Authors: Amy C Degnim; Carol Reynolds; Gouri Pantvaidya; Shaheen Zakaria; Tanya Hoskin; Sunni Barnes; Margaret V Roberts; Peter C Lucas; Kevin Oh; Meryem Koker; Michael S Sabel; Lisa A Newman Journal: Am J Surg Date: 2005-10 Impact factor: 2.565
Authors: Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow Journal: JAMA Date: 2011-02-09 Impact factor: 56.272
Authors: Anees B Chagpar; Charles R Scoggins; Robert C G Martin; David J Carlson; Alison L Laidley; Souzan E El-Eid; Terre Q McGlothin; Kelly M McMasters Journal: Am J Surg Date: 2006-12 Impact factor: 2.565
Authors: Oldrich Coufal; Tomás Pavlík; Pavel Fabian; Rita Bori; Gábor Boross; István Sejben; Róbert Maráz; Jaroslav Koca; Eva Krejcí; Iva Horáková; Vendula Foltinová; Pavlína Vrtelová; Vojtech Chrenko; Wolde Eliza Tekle; Mária Rajtár; Mihály Svébis; Vuk Fait; Gábor Cserni Journal: Pathol Oncol Res Date: 2009-05-15 Impact factor: 3.201
Authors: I Barco; M García Font; A García-Fernández; N Giménez; M Fraile; J M Lain; E Vallejo; S González; L Canales; J Deu; M C Vidal; M Rodríguez-Carballeira; A Pessarrodona; C Chabrera Journal: Clin Transl Oncol Date: 2017-08-14 Impact factor: 3.405
Authors: Inne J Den Toom; Elisabeth Bloemena; Stijn van Weert; K Hakki Karagozoglu; Otto S Hoekstra; Remco de Bree Journal: Eur Arch Otorhinolaryngol Date: 2016-08-25 Impact factor: 2.503